Gilead Sciences stock falls 1.11 percent despite revenue growth
Published on 09/25/2026 at 11:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock (ISIN US3755581036) stood at USD 149.69 on Nasdaq on September 24, 2026, down 1.11 percent from the prior close of USD 151.37. The latest quarterly report combined revenue growth with a large acquisition-related adjusted loss, while HSBC raised its price target days earlier.
Revenue beats consensus estimates
In second-quarter 2026, Gilead reported revenue of USD 7.80 billion, up 10 percent from the prior-year quarter and above the Zacks consensus estimate of USD 7.37 billion. According to Zacks on September 18, 2026, product sales excluding Veklury rose 10 percent to USD 7.60 billion.
The adjusted loss was USD 6.75 per share, narrower than the USD 7.07 consensus loss. The comparison with adjusted earnings of USD 2.01 per share in the year-ago quarter shows how strongly acquisition-related in-process research and development expenses affected the reported result.
Guidance points to base-business growth
Gilead's updated 2026 product-sales guidance stands at USD 30.10 billion to USD 30.40 billion, compared with the prior range of USD 30.00 billion to USD 30.40 billion. The company also lifted its HIV sales-growth outlook to 9 percent to 10 percent from 8 percent, according to Zacks.
The portfolio split is important for interpreting the loss. HIV product sales rose 12 percent to USD 5.69 billion, while cell-therapy sales fell 14 percent to USD 417 million in the second quarter of 2026.
HSBC lifts its price target
HSBC increased its Gilead price target to USD 175 from USD 155 and maintained a Buy rating in a research note dated September 10, 2026. MarketBeat also reported a Moderate Buy consensus and an average target of USD 158.78.
Gilead declared a quarterly dividend of USD 0.82 per share payable on September 29, 2026, according to MarketBeat. For investors, the central tension is clear: operating sales are expanding, but the acquisition charge makes adjusted earnings the more volatile indicator.
Stock remains below its yearly high
Gilead Sciences stock was USD 149.69 on Nasdaq on September 24, 2026, with a 52-week range of USD 108.46 to USD 157.29 and market capitalization of USD 185.61 billion. Trading volume was 5,074,540 shares on that date.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: Nasdaq
- Price (as of September 24, 2026, 4:00 p.m. ET): USD 149.69
- Market capitalization: USD 185.61 billion (as of September 24, 2026)
- 52-week range: USD 108.46-157.29 (as of September 24, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: Nasdaq 100
